WO2007076423A3 - INHIBITORS OF Akt ACTIVITY - Google Patents
INHIBITORS OF Akt ACTIVITY Download PDFInfo
- Publication number
- WO2007076423A3 WO2007076423A3 PCT/US2006/062453 US2006062453W WO2007076423A3 WO 2007076423 A3 WO2007076423 A3 WO 2007076423A3 US 2006062453 W US2006062453 W US 2006062453W WO 2007076423 A3 WO2007076423 A3 WO 2007076423A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitors
- akt activity
- activity
- compounds
- akt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Invented are novel thiophene compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06846739A EP1968568A4 (en) | 2005-12-22 | 2006-12-21 | INHIBITORS OF Akt ACTIVITY |
JP2008547763A JP2009521504A (en) | 2005-12-22 | 2006-12-21 | Akt activity inhibitor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75303305P | 2005-12-22 | 2005-12-22 | |
US60/753,033 | 2005-12-22 | ||
US79319806P | 2006-04-19 | 2006-04-19 | |
US60/793,198 | 2006-04-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007076423A2 WO2007076423A2 (en) | 2007-07-05 |
WO2007076423A3 true WO2007076423A3 (en) | 2007-11-29 |
Family
ID=38218824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/062453 WO2007076423A2 (en) | 2005-12-22 | 2006-12-21 | INHIBITORS OF Akt ACTIVITY |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1968568A4 (en) |
JP (1) | JP2009521504A (en) |
WO (1) | WO2007076423A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US8933085B2 (en) | 2010-11-19 | 2015-01-13 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US8933086B2 (en) | 2005-12-13 | 2015-01-13 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors |
US8987443B2 (en) | 2013-03-06 | 2015-03-24 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
US9156845B2 (en) | 2012-06-29 | 2015-10-13 | Pfizer Inc. | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US9216984B2 (en) | 2009-05-22 | 2015-12-22 | Incyte Corporation | 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9334274B2 (en) | 2009-05-22 | 2016-05-10 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9359358B2 (en) | 2011-08-18 | 2016-06-07 | Incyte Holdings Corporation | Cyclohexyl azetidine derivatives as JAK inhibitors |
US9464088B2 (en) | 2010-03-10 | 2016-10-11 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US9487521B2 (en) | 2011-09-07 | 2016-11-08 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
US9580416B2 (en) | 2014-07-02 | 2017-02-28 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1926735A1 (en) | 2005-09-22 | 2008-06-04 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
EA200870117A1 (en) | 2005-12-23 | 2008-12-30 | Смитклайн Бичам Корпорейшн | AZAINDOL INHIBITORS AURORA-KINAZ |
GB0617161D0 (en) * | 2006-08-31 | 2006-10-11 | Vernalis R&D Ltd | Enzyme inhibitors |
CA2673038C (en) | 2006-12-22 | 2015-12-15 | Incyte Corporation | Substituted tricyclic heteroaryl compounds as janus kinase inhibitors |
ES2543325T3 (en) * | 2007-02-07 | 2015-08-18 | Glaxosmithkline Llc | Akt activity inhibitors |
UY30892A1 (en) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | AKT ACTIVITY INHIBITORS |
CL2008001709A1 (en) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others. |
PL2173752T5 (en) | 2007-06-13 | 2022-12-05 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
AU2008331733A1 (en) | 2007-11-02 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | [1H- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase C-theta |
ES2604555T3 (en) * | 2007-12-07 | 2017-03-07 | Vertex Pharmaceuticals Incorporated | Process for producing cycloalkylcarboxyamido-pyridinebenzoic acids |
JP5635910B2 (en) * | 2008-01-09 | 2014-12-03 | アレイ バイオファーマ、インコーポレイテッド | 5H-cyclopenta [d] pyrimidine as an AKT protein kinase inhibitor |
EA017218B1 (en) | 2008-03-11 | 2012-10-30 | Инсайт Корпорейшн | Azetidine and cyclobutane derivatives as jak inhibitors |
US20110092423A1 (en) * | 2008-06-26 | 2011-04-21 | GlaxoSmithKline, LLC | INHIBITORS OF Akt ACTIVITY |
EP2400964A4 (en) | 2009-01-30 | 2012-08-01 | Glaxosmithkline Llc | Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
WO2010093885A1 (en) * | 2009-02-12 | 2010-08-19 | Glaxosmithkline Llc | Inhibitors of akt activity |
CN102459221A (en) * | 2009-04-30 | 2012-05-16 | 住友化学株式会社 | Thiophene derivative |
EP2486041B1 (en) | 2009-10-09 | 2013-08-14 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
DK2574168T3 (en) | 2010-05-21 | 2016-05-09 | Incyte Holdings Corp | Topical formulation to a jak inhibitor |
CA2827673C (en) | 2011-02-18 | 2020-10-27 | Novartis Pharma Ag | Mtor/jak inhibitor combination therapy |
US9358229B2 (en) | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
CN104507923B (en) * | 2012-08-02 | 2018-02-09 | 内尔维阿诺医学科学有限公司 | Substituted pyroles activating agent as kinase inhibitor |
DE102012019369A1 (en) | 2012-10-02 | 2014-04-03 | Merck Patent Gmbh | 7-Azaindolderivat |
MY191357A (en) | 2012-11-15 | 2022-06-19 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
TW201533043A (en) * | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors |
SG10201912203XA (en) | 2013-08-07 | 2020-02-27 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
WO2015092592A1 (en) | 2013-12-17 | 2015-06-25 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
CN103833725B (en) * | 2014-03-03 | 2016-06-08 | 上海北卡医药技术有限公司 | A kind of method synthesizing 5-N-tertiary butoxy carbonyl-5-N-methylamino-2-thiophenic acid |
CN108137586B (en) | 2015-09-14 | 2021-04-13 | 辉瑞大药厂 | Novel imidazo [4,5-c ] quinoline and imidazo [4,5-c ] [1,5] naphthyridine derivatives as LRRK2 inhibitors |
WO2017156071A1 (en) | 2016-03-09 | 2017-09-14 | Blade Therapeutics, Inc. | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof |
US11292801B2 (en) | 2016-07-05 | 2022-04-05 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
AU2017336523B2 (en) | 2016-09-28 | 2022-07-21 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
CN108948002A (en) * | 2017-05-19 | 2018-12-07 | 厦门大学 | Five yuan and hexa-atomic nitrogen heteroaromatic rings class compound, preparation method, Pharmaceutical composition and its application |
KR20190043437A (en) * | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | Heterocylic compound as a protein kinase inhibitor |
TW201924683A (en) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2019114741A1 (en) * | 2017-12-13 | 2019-06-20 | 南京明德新药研发股份有限公司 | Salt serving as akt inhibitor and crystal thereof |
CN112105608B (en) | 2018-01-30 | 2023-07-14 | 因赛特公司 | Process for the preparation of (1- (3-fluoro-2- (trifluoromethyl) isonicotinyl) piperidin-4-one |
MX2022012285A (en) | 2018-03-30 | 2023-08-15 | Incyte Corp | Treatment of hidradenitis suppurativa using jak inhibitors. |
WO2019195634A1 (en) * | 2018-04-04 | 2019-10-10 | Epiodyne, Inc. | Opioid receptor modulators and products and methods related thereto |
CN112888440A (en) | 2018-10-16 | 2021-06-01 | 豪夫迈·罗氏有限公司 | Use of Akt inhibitors in ophthalmology |
WO2020150417A2 (en) * | 2019-01-17 | 2020-07-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CN112266349B (en) * | 2020-11-17 | 2022-02-15 | 上海凌凯医药科技有限公司 | Method for preparing 2-amino-4-methyl-1-propyl-1H-pyrrole-3-carbonitrile |
CN115073469B (en) * | 2021-03-15 | 2023-12-22 | 药雅科技(上海)有限公司 | Preparation and application of pyrrolopyrimidine compound as kinase inhibitor |
WO2022216717A1 (en) * | 2021-04-05 | 2022-10-13 | The Cleveland Clinic Foundation | Citron kinase inhibitors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050130954A1 (en) * | 2003-11-21 | 2005-06-16 | Mitchell Ian S. | AKT protein kinase inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5019612B2 (en) * | 2004-04-02 | 2012-09-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | Azaindoles and other protein kinases useful as inhibitors of ROCK |
EP2325184A1 (en) * | 2004-06-30 | 2011-05-25 | Vertex Pharmceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
JP2008520745A (en) * | 2004-11-22 | 2008-06-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Bicyclic inhibitors of Rho kinase |
ES2380795T3 (en) * | 2005-05-20 | 2012-05-18 | Vertex Pharmaceuticals, Inc. | Pyrrolopyridines useful as protein kinase inhibitors |
-
2006
- 2006-12-21 EP EP06846739A patent/EP1968568A4/en not_active Withdrawn
- 2006-12-21 JP JP2008547763A patent/JP2009521504A/en not_active Withdrawn
- 2006-12-21 WO PCT/US2006/062453 patent/WO2007076423A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050130954A1 (en) * | 2003-11-21 | 2005-06-16 | Mitchell Ian S. | AKT protein kinase inhibitors |
Non-Patent Citations (1)
Title |
---|
See also references of EP1968568A4 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9206187B2 (en) | 2005-12-13 | 2015-12-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase |
US8933086B2 (en) | 2005-12-13 | 2015-01-13 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors |
US8946245B2 (en) | 2005-12-13 | 2015-02-03 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US9334274B2 (en) | 2009-05-22 | 2016-05-10 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9216984B2 (en) | 2009-05-22 | 2015-12-22 | Incyte Corporation | 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9464088B2 (en) | 2010-03-10 | 2016-10-11 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US8933085B2 (en) | 2010-11-19 | 2015-01-13 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
US9023840B2 (en) | 2011-06-20 | 2015-05-05 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US9359358B2 (en) | 2011-08-18 | 2016-06-07 | Incyte Holdings Corporation | Cyclohexyl azetidine derivatives as JAK inhibitors |
US9487521B2 (en) | 2011-09-07 | 2016-11-08 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US9156845B2 (en) | 2012-06-29 | 2015-10-13 | Pfizer Inc. | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors |
US9221845B2 (en) | 2013-03-06 | 2015-12-29 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US8987443B2 (en) | 2013-03-06 | 2015-03-24 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
US9580416B2 (en) | 2014-07-02 | 2017-02-28 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
Also Published As
Publication number | Publication date |
---|---|
EP1968568A4 (en) | 2011-04-13 |
WO2007076423A2 (en) | 2007-07-05 |
JP2009521504A (en) | 2009-06-04 |
EP1968568A2 (en) | 2008-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007076423A3 (en) | INHIBITORS OF Akt ACTIVITY | |
WO2008098104A8 (en) | Inhibitors of akt activity | |
WO2007058850A3 (en) | Inhibitors of akt activity | |
WO2006113837A3 (en) | Inhibitors of akt activity | |
WO2009158374A3 (en) | Inhibitors of akt activity | |
WO2009158371A8 (en) | Inhibitors of akt activity | |
WO2007064872A3 (en) | Urea compounds useful in the treatment of cancer | |
MXPA06001134A (en) | INHIBITORS OF Akt ACTIVITY. | |
WO2007064945A3 (en) | Cancer therapies and pharmaceutical compositions used therein | |
WO2007061874A3 (en) | Methods and compositions for use in treating cancer | |
IL174952A0 (en) | Sulfoximine-substituted pyrimidines for use as cdk and/or vegf inhibitors, the production thereof and their use as drugs | |
AP2139A (en) | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors. | |
WO2007067781A3 (en) | 9-membered heterobicyclic compounds as inhibitors of protein kinases | |
WO2008054676A3 (en) | Medical devices and methods of using the same | |
AU2006226897B2 (en) | Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors | |
TW200801008A (en) | Protein kinase inhibitors | |
WO2007149482A3 (en) | Xanthohumol based protein kinase modulation cancer treatment | |
WO2008156614A3 (en) | Imidazopyrazines as protein kinase inhibitors | |
WO2004034990A3 (en) | Methods and compositions for use in treating cancer | |
WO2009009173A3 (en) | Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases | |
WO2006015263A3 (en) | Lonidamine analogs | |
WO2006009765A3 (en) | Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells | |
WO2007059202A3 (en) | Pyrazolyl urea derivatives useful in the treatment of cancer | |
WO2006127900A3 (en) | Tl1a in the treatment of disease | |
AU2006321904A8 (en) | 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008547763 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006846739 Country of ref document: EP |